![]() Kite is obligated to make certain milestone payments upon the achievement of clinical, regulatory and sales milestones relating to TCR-based product candidates. To further strengthen its TCR product platform and established a European presence the company acquired TCF, which has been renamed Kite Pharma EU.įinancial terms of Kite's acquisition of TCF include an upfront payment of up to EURO20.0M (approximately $21.0M USD) to TCF shareholders, licensors and employees, of which EURO3.8M (approximately $4.0M USD) will be paid in Kite stock. Kite Pharma (KITE) delivered a negative earnings surprise in the first quarter of 2015. Shares have added about 6.3 in that time. Shares have added about 6.3 in that time frame, outperforming the market. KITE is a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products based on CAR and TCR gene therapy platforms for the treatment of cancer. A month has gone by since the last earnings report for Kite Pharma, Inc. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. representative turnover intention: A growing concern in Bangladeshs pharmaceuticals industry. ![]() (TCF), a privately held Dutch company and former participant of the Venture Challenge, has been acquired by Kite pharma, INc (KITE). And, The Kite Runner is a tale of humans and humanity. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |